April 17, 2012
Otsuka Pharmaceutical Co., Ltd.
New Antipsychotic Agent "ABILIFY® OD Tablets"
Pursues Agreeability for Patients, Enables easy Adherence
- ABILIFY, one of the world's ten best-selling drugs, will go on sale in an agreeable dosage form for patients in Japan: "ABILIFY OD Tablets." In addition to high tolerance, the new form enables easy adherence.
- The sweet-tasting tablet dissolves orally in seconds; compared with other tablets, it is easily ingested by patients with difficulty swallowing, including seniors and women. The tablet can be ingested without water and thus can be reliably taken while away from home.
- A 24mg tablet has been added as a single-tablet dosage for initial treatment of manic symptoms associated with bipolar disorder.
Tokyo, Japan - Otsuka Pharmaceutical Co., Ltd. today announced that on May 11 it will begin sales in Japan of ABILIFY OD Tablets in four dosages (3mg, 6mg, 12mg, and 24mg), offering a new dosage form of the antipsychotic agent ABILIFY (aripiprazole).
Information in this news release was current as of the original release date.